This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Windhover Information Names D-Tagatose One Of Top 10 Most Promising CV/Metabolic Drugs In Development

BETHESDA, Md., Sept. 15 /PRNewswire/ -- Spherix Incorporated (Nasdaq CM: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that the Company's pharmaceutical product, D-tagatose, has been selected as one of the top 10 most promising cardiovascular/metabolic therapies in development.  The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries and publisher of IN VIVO and Start-Up.  Spherix has been invited to present its data on D-tagatose at Windhover's Therapeutic Alliances Cardiovascular Conference in Boston on November 3-4, 2010.

"Recognition of D-tagatose by Windhover Information underscores the value we see in it as potential therapy for Type 2 diabetes," said Dr. Claire L. Kruger, Chief Executive Officer of Spherix.  "Windhover's Therapeutic Alliance Partnerships is the industry's most targeted, efficient, strategic-level partnering meeting for life science companies seeking partnerships in the cardiovascular and metabolic therapeutic areas."

The Top 10 selection was made by an independent committee headed by Marc Wortman, Ph.D., a regular contributor to Windhover's Start-Up, and Jun Huangpu, Ph.D., MBA, founder of Cobbs Creek Healthcare LLC.  The committee evaluated hundreds of compounds currently in development for the treatment of cardiovascular disease and metabolic disorders.

According to Windhover, evaluation criteria include:
  • Unmet medical need
  • Market potential
  • Multi-level marketing opportunities
  • Potential for new opportunities beyond initial indications
  • Diversity of indications
  • History of the molecule and drug
  • Strong science
  • Strong company

Data from the Naturlose (D-tagatose) Efficacy Evaluation Trial (NEET) trial are currently being analyzed.  Spherix plans to announce the results of the Phase 3 trial in the coming weeks.  NEET was initiated in 2007 and is a double-blind, placebo-controlled study designed to evaluate the safety and efficacy of D-tagatose as a monotherapy as an adjunct to diet and exercise.  The primary endpoint is change in HbA1c, with secondary endpoints that include triglycerides, glucose and insulin profiles, and changes in body weight.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SPEX $0.46 0.00%
AAPL $112.12 0.00%
FB $93.24 0.00%
GOOG $643.61 0.00%
TSLA $220.69 0.00%


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs